This prestigious award recognizes young investigators working in areas of translational research. Up to three awards of $12,000 each are presented annually. This award, which was established in 2010, is supported by Pfizer Ophthalmics through the ARVO Foundation.
Nominations open now
Deadline: Sept. 1, 2019
2019 Pfizer Ophthalmics Carl Camras Translational Research Award recipient
Yali Jia, PhD
Oregon Health & Science University
About Dr. Jia
Yali Jia, PhD is an Associate Professor of Ophthalmology and Biomedical Engineering at the Oregon Health & Science University (OHSU). Dr. Jia earned her PhD in Biomedical Engineering from OHSU in 2010 under the guidance of Dr. Ruikang Wang. Dr. Jia completed her post-doctoral training with Dr. David Huang at Casey Eye Institute in 2013. Dr. Jia is known for her innovations in optical coherence tomographic angiography (OCTA) and the application to eye diseases. She developed split-spectrum amplitude-decorrelation angiography (SSADA), which is a major breakthrough that transitioned OCTA from a purely research technology to the clinic. Her original paper on this subject, published in 2012, has been cited 900 times. She was awarded 3 NIH research project grants that supported the initial works that demonstrated clinical applications of OCTA in retinal diseases. She is the technical leader in Casey Reading Center. Her OCTA reading software (COOL-ART) has been used by several large clinical studies and many international collaborators. She has published more than 100 peer-reviewed journal articles with over 6000 citations. She has co-edited 3 books. Dr. Jia and her team are also pursuing research in other novel OCT technologies including the use of nanoparticles as OCT contrast agents, Doppler OCT to measure retinal blood flow, spectroscopic OCT to measure tissue oxymetry, and the use of artificial intelligence to detect and classify retinal pathologies.
Dr. Jia says of receiving this award, "This award is huge encouragement for me, women scientists and the OCT and OCTA community. I will continue to advance frontiers in my active research program and I believe the future of OCTA will have a major impact on the diagnosis and management of ocular diseases."